Object

Support for innovative small molecule and biologic (antibodies, oligonucleotides, peptides, gene therapy etc.) drug development programs for FTD. Drug targets in the areas of inflammation and proteostasis will be considered high priority.

Main features

The RFP supports:

- Lead optimization of novel disease-modifying compounds, including medicinal chemistry refinement and in vitro ADME.

- In vivo testing of novel lead compounds, biologics, repurposed drug candidates in relevant animal models for pharmacokinetics, dose-range finding, target engagement, in vivo efficacy, and/or preliminary rodent tolerability studies.

- This RFP does NOT support target identification, target validation, assay development, high-throughput and high-content screening. IND-enabling work is supported through ADDF's PACT RFP.

Funding

Budgets averaging $100,000-$150,000 are recommended.

Duration

1 year with potential for follow-on funding.

Deadlines

Letter of Intent: July 10th, 2020 Must be received by 5:00 pm ET on the deadline date.

Invited Full Proposal: August 7th, 2020 Must be received by 5:00 pm ET on the deadline date.

In case of interest, please contact with FSJD Research Department.